(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 296.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.55%.
Milestone Pharmaceuticals's revenue in 2026 is $1,784,000.On average, 8 Wall Street analysts forecast MIST's revenue for 2026 to be $684,863,388, with the lowest MIST revenue forecast at $244,016,041, and the highest MIST revenue forecast at $915,060,153. On average, 8 Wall Street analysts forecast MIST's revenue for 2027 to be $3,193,746,681, with the lowest MIST revenue forecast at $1,342,088,224, and the highest MIST revenue forecast at $4,523,011,613.
In 2028, MIST is forecast to generate $15,965,620,955 in revenue, with the lowest revenue forecast at $6,954,457,163 and the highest revenue forecast at $37,412,887,970.